To evaluate patient experience of Basal-IQ® technology during real-world use. While the patient experience scores reported in clinical trials are important, real-world use provides enhanced data insights to estimate ongoing sustainability and usefulness of diabetes technologies.
In May 2019, users of the t:slim X2™ insulin pump with Basal-IQ technology voluntarily responded to an online survey via Qualtrics, an online survey software. Nine metrics measured satisfaction, trust, usability, and utility of the system on a 5-point Likert scale.
Participants reported high levels of satisfaction, trust, and overall usability. Survey findings showed that users perceived that the system has helped improved their sleep and overall blood glucose control. Results did not vary by age or prior therapy.
Study findings supported a very positive real-world experience of Basal-IQ technology in a large sample of users. Patient satisfaction with diabetes device technology has shown to be a critical factor in successful long-term diabetes management.
Consult user guides for our pumps, infusion sets, predictive technology, and reporting app.View Documentation
Use our education tutorials to train your patients or CDEs on our easy-to-use products.View Resources
1. Forlenza GP, Li Z, Buckingham BA, et al. Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial. Diabetes Care. 2018;41(10):2155-2161.
2. Tanenbaum ML, IturraldeE, Hanes SJ, et al. Trust in hybrid closed loop among people with diabetes: perspectives of experienced system users. J Health Psychol. doi:10.1177/1359105317718615.
3. Weissberg-Benchell J, Hood K, LaffelL, et al. Toward development of psychosocial measures for automated insulin delivery. J Diabetes Sci Technol. 2016;10(3):799-801.
4. Farrington C. Psychosocial impacts of hybrid closed-loop systems in the management of diabetes: a review. DiabetMed. 2018;35(4), 436-449.
Important Safety Information
Caution: Federal (USA) law restricts the t:slim X2 insulin pump and the t:slim X2 insulin pump with Basal-IQ technology to sale by or on the order of a physician. The t:slim X2 insulin pump with Basal-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Basal-IQ technology, and a compatible integrated continuous glucose monitor (iCGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When used with a compatible CGM, the t:slim X2 insulin pump with Basal-IQ technology can be used to suspend insulin delivery based on CGM sensor readings. The pump and the System are indicated for use in individuals 6 years of age and greater. The pump and the System are intended for single patient use. The pump and the System are indicated for use with NovoLog or Humalog U-100 insulin. The System is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. For additional important safety information, visit www.tandemdiabetes.com/safetyinfo.